Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung CancerAlexander Drilon, Vivek Subbiah, Vamsidhar Velcheti et al.|New England Journal of Medicine|2020Cited by 835
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapiesShogo Kumagai, Hiroyoshi Nishikawa, Yosuke Togashi et al.|Nature Immunology|2020Cited by 810
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trialsAlexander Drilon, Robert C. Doebele, Salvatore Siena et al.|The Lancet Oncology|2019Cited by 537
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancerGeoffrey R. Oxnard, Myung‐Ju Ahn, J.C.-H. Yang et al.|Annals of Oncology|2020Cited by 443
Trastuzumab Deruxtecan in Patients With <i>HER2</i>-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 TrialKōichi Goto, Pasi A. Jänne, Yasushi Goto et al.|Journal of Clinical Oncology|2023Cited by 293